NFE2L2 and ovarian carcinoma: Also to our surprise, we have not observed the induction of chemoresistance upon UDCA treatment neither in cisplatin resistant, nor in cisplatin sensitive A2780 cells, despite the widespread literature reports on resistance against numerous chemotherapy agents upon NRF2 induction in multiple cancers, including ovarian cancer [57, 59, 89–92].